Related references
Note: Only part of the references are listed.Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Antonio Omuro et al.
NEURO-ONCOLOGY (2023)
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)
Matthias Preusser et al.
NEURO-ONCOLOGY (2022)
Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review
Katherine Belanger et al.
BMC CANCER (2022)
Prognostic impact of genetic alterations and methylation classes in meningioma
Anna S. Berghoff et al.
BRAIN PATHOLOGY (2022)
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Michael Lim et al.
NEURO-ONCOLOGY (2022)
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
Priscilla K. Brastianos et al.
NATURE COMMUNICATIONS (2022)
Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas
D. Bradley Welling et al.
LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY (2021)
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1
F. Andre et al.
ANNALS OF ONCOLOGY (2021)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2021)
Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study
Thomas Graillon et al.
NEURO-ONCOLOGY (2021)
Crispr/Cas-based modeling of NF2 loss in meningioma cells
Natalie Waldt et al.
JOURNAL OF NEUROSCIENCE METHODS (2021)
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas
Jacky Yeung et al.
NEURO-ONCOLOGY (2021)
A clinically applicable integrative molecular classification of meningiomas
Farshad Nassiri et al.
NATURE (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
EANO guideline on the diagnosis and management of meningiomas
Roland Goldbrunner et al.
NEURO-ONCOLOGY (2021)
Meningioma metastases: incidence and proposed screening paradigm
Cecilia L. Dalle Ore et al.
JOURNAL OF NEUROSURGERY (2020)
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
Thomas Graillon et al.
CLINICAL CANCER RESEARCH (2020)
Sonic Hedgehog Signaling in Organogenesis, Tumors, and Tumor Microenvironments
Kuo-Shyang Jeng et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations
A. Das et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.
Priscilla Kaliopi Brastianos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
KLF4K409Q-mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment
Niklas von Spreckelsen et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)
CDKN2A/Bhomozygous deletion is associated with early recurrence in meningiomas
Philipp Sievers et al.
ACTA NEUROPATHOLOGICA (2020)
Meningioma cells express primary cilia but do not transduce ciliary Hedgehog signals
Sarah Findakly et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)
Analysis of the inflammatory tumor microenvironment in meningeal neoplasms
Anna Sophie Berghoff et al.
CLINICAL NEUROPATHOLOGY (2020)
Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression
Shirin Karimi et al.
SCIENTIFIC REPORTS (2020)
Individual-patient prediction of meningioma malignancy and survival using the Surveillance, Epidemiology, and End Results database
Jeremy T. Moreau et al.
NPJ DIGITAL MEDICINE (2020)
Cytokines in the Treatment of Cancer
Kevin C. Conlon et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2019)
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group
Raymond Y. Huang et al.
NEURO-ONCOLOGY (2019)
Systemic and local immunosuppression in patients with high-grade meningiomas
Yuping D. Li et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Trends in intracranial meningioma incidence in the United States, 2004-2015
Dong-Dong Lin et al.
CANCER MEDICINE (2019)
Incidence, mortality and outcome of meningiomas: A population-based study from Germany
Bernd Holleczek et al.
CANCER EPIDEMIOLOGY (2019)
Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma
Anne Guyot et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas
Sally R. Williams et al.
JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE (2019)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
DNA methylation-based classification of central nervous system tumours
David Capper et al.
NATURE (2018)
Advances in meningioma genetics: novel therapeutic opportunities
Matthias Preusser et al.
NATURE REVIEWS NEUROLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
AKT Inhibition in Solid Tumors With AKT1 Mutations
David M. Hyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
Felix Sahm et al.
LANCET ONCOLOGY (2017)
Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence
Uemmueguelsuem Yesiloez et al.
NEURO-ONCOLOGY (2017)
Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo
Hiroyuki Takeda et al.
ONCOTARGET (2017)
Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma
Adriana Olar et al.
ACTA NEUROPATHOLOGICA (2017)
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Elena Mazza et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma
Julia Furtner et al.
NEURO-ONCOLOGY (2016)
Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma
Seunggu J. Han et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma
Kent C. Shih et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma
Malak Abedalthagafi et al.
NEURO-ONCOLOGY (2016)
Extent of Resection and Overall Survival for Patients With Atypical and Malignant Meningioma
Ayal A. Aizer et al.
CANCER (2015)
Somatostatin Receptor-Targeted Radiopeptide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial
Nicolas Marincek et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
Ziming Du et al.
ONCOTARGET (2015)
The Role of Mifepristone in Meningiomas Management: A Systematic Review of the Literature
Giulia Cossu et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
Thomas J. Kaley et al.
NEURO-ONCOLOGY (2015)
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma
Andrew D. Norden et al.
NEUROLOGY (2015)
Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy
Marta Simo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas
Jeffrey J. Raizer et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review
Thomas Kaley et al.
NEURO-ONCOLOGY (2014)
Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2-Deficient Meningioma Growth
Sarah S. Burns et al.
CANCER RESEARCH (2013)
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
Priscilla K. Brastianos et al.
NATURE GENETICS (2013)
Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
Victoria E. Clark et al.
SCIENCE (2013)
Trabectedin Has Promising Antineoplastic Activity in High-Grade Meningioma
Matthias Preusser et al.
CANCER (2012)
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma
Marc C. Chamberlain
JOURNAL OF NEURO-ONCOLOGY (2012)
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
Emil Lou et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Atypical and anaplastic meningiomas treated with bevacizumab
Lakshmi Nayak et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas
Matthew L. Bush et al.
NEURO-ONCOLOGY (2011)
Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma
Derek R. Johnson et al.
NEURO-ONCOLOGY (2011)
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
Andrew D. Norden et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2009)
LONG-TERM RECURRENCE RATES OF ATYPICAL MENINGIOMAS AFTER GROSS TOTAL RESECTION WITH OR WITHOUT POSTOPERATIVE ADJUVANT RADIATION
Manish K. Aghi et al.
NEUROSURGERY (2009)
Interferon-α for Recurrent World Health Organization Grade 1 Intracranial Meningiomas
Marc C. Chamberlain et al.
CANCER (2008)
Salvage chemotherapy with CPT-11 for recurrent meningioma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Temozolomide for treatment-resistant recurrent meningioma
MC Chamberlain et al.
NEUROLOGY (2004)
Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study
S Pistolesi et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2004)
Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma
WP Mason et al.
JOURNAL OF NEUROSURGERY (2002)
Share Paper
